There was bleak news yesterday for hundreds of workers at a north Dublin pharmaceutical plant as they were told they will lose their jobs over the next two years.
US-based pharmaceutical company Viatris announced 440 jobs are to go at the company's plant in Baldoyle as part of a major restructuring plan.
The company, which employs 45,000 people worldwide, announced that five of its plants around the world will be affected.
It confirmed that its Baldoyle operation would be among them.
The company said it intends to "close, downsize or divest" up to 15 manufacturing facilities globally that are deemed to be "no longer viable either due to surplus capacity, challenging market dynamics or a shift in its product portfolio toward more complex products".
The company said it expects that 20pc of its current workforce of around 9,000 employees will be affected by the streamlining.
Viatris was formed out of a merger between pharmaceutical giants Mylan and Upjohn, Pfizer's off-patent medicine division, just last month.
The Mylan plant in Baldoyle is an oral solid-dose medicine manufacturer. The firm could not be reached for comment yesterday.
Meanwhile, Tánaiste and Employment Minister Leo Varadkar said last night: "This is really devastating news for those working in Viatris and their families. It has been an exceptionally difficult year for everyone.
"This will come as another blow, especially so close to Christmas, although I am assured that there will be no immediate reductions and that the majority of the workforce will remain employed until late 2022.
"I understand that this development is not related to Covid-19, but instead related to a global restructuring.
"Despite this disappointing decision, Viatris has made it clear that it remains fully committed to Ireland and even after this announcement they will employ more than 1,400 across the country."